Tigecycline: What is it, and where should it be used?

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 4, 2005, Pages 611-614

  Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

GAR 936; Glycylcyclines; Tetracyclines

Indexed keywords

AMINOGLYCOSIDE; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; METRONIDAZOLE; MINOCYCLINE; NITROFURANTOIN; POLYMYXIN DERIVATIVE; QUINOLONE; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG RESEARCH; DRUG STRUCTURE; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PNEUMONIA; PSEUDOMONAS; SKIN INFECTION; STRUCTURE ACTIVITY RELATION; SURGICAL INFECTION; TISSUE DISTRIBUTION; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MINOCYCLINE; MOLECULAR STRUCTURE;

EID: 27144457701     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki291     Document Type: Article

References (33)

1. Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-4.
2. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201-9.
3. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936). d Antimicrob Chemother 2002; 49: 479-87.
4. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-81.
5. Olivia ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Surg 2005; in press.
6. Fomin P, Beuran M, Gradauskas A et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3: 35-47.
7. Sacchidanad S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a Phase 3, randomized, double-blind trial. Int J Infect Dis 2005; (16 August 2005, published online).
8. Breedt J, Teras J, Gardovskis J et al. The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind Phase 3 comparison study with vancomycin/ aztreonam. Antimicrob Agents Chemother 2005; in press.
9. Testa RT, Petersen PJ, Jacobus NV et al. In vitroand in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270-7.
10. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999; 9: 1459-62.
11. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
12. Fluit AC, Florijn A, Verhoef J et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636-8.
13. Chopra I. Genetic and biochemical basis of tetracycline resistance. J Antimicrob Chemother 1986; 18 (Suppl C): 51-6.
14. Bauer G, Berens C, Projan SJ et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-9.
15. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother2005; 49: 791-3.
16. Dean CR, Visalli MA, Projan SJ et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-8.
17. Yang W, Moore IF, Koteva KP et al. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem 2004; 279: 52346-52.
18. Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53: 1018-32.
19. Jacobus NV, McDermott LA, Ruthazer R et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004; 48: 1034-6.
20. Hope R, Warner M, Ward ME. Effect of medium type, age and aeration on the MICs of tigecycline and other tetracyclines. Clin Microbiol Infect 2005; 11 Suppl 2: 246.
21. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
22. Postier RG, Green SL, Klein SR et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-14.
23. Nosocomial Infection National Surveillance Service. Surveillance of Surgical-Site Infection in English Hospitals 1997-2001. Health Protection Agency, 2002. http://www.hpa.org.uk/infections/publications/ ninns/NINSS-SSI2000.pdf (20 May 2005, date last accessed).
24. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
25. Munday CJ, Whitehead GM, Todd NJ et al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628-33.
26. Livermore DM, Hawkey PM. CTX-M: Changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; (8 July 2005, published online).
27. Livermore DM. Threat from the pink corner. Ann Med 2003; 35: 226-34.
28. Coelho J, Woodford N, Turton J et al. Multiresistant Acinetobacterin the UK: How big a threat? J Hosp Infect 2004; 58: 167-9.
29. Wilson P. Endemic, highly resistant Acinetobacter in the intensive care unit - is tigecycline the answer? In: Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic. Abstract P938. Clin Microbiol Infect 2004; 10 Suppl 3: 247.
30. Wood GC, Hanes SD, Boucher BA et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med 2003; 29: 2072-6.
31. Weigelt J, Kaafarani HM, Itani KM et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188: 760-6.
32. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97.
33. Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 2000; 6: 277-82.